Bimonthly high dose leucovorin and 5‐fluorouracil 48‐hour infusion with interferon‐alpha‐2a in patients with advanced colorectal carcinoma

The rationale for the modulation of 5‐fluorouracil (5‐FU) with interferon‐alpha (IFN) is inhibition of 5‐FU catabolism and 5‐FU resistance. Clinical trials have shown debatable results when IFN is given in high doses with 5‐FU used as a bolus alone or in combination with leucovorin (LV). A first‐line Phase II study was performed in 50 patients with metastatic colorectal carcinoma who were given a bimonthly combination of high dose LV, a high dose 48‐hour infusion of 5‐FU, and a low dose of IFN.

[1]  L. Thill,et al.  Inhibition of dihydropyrimidine dehydrogenase by α-interferon: experimental data on human tumor cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[2]  C. Tournigand,et al.  716 Oxaliplatin with high-dose folinic acid and 5-fluorouracil 48 H infusion in pretreated metastatic colorectal cancer (CRC) , 1995 .

[3]  R. Hoffman,et al.  Recombinant human interferon alpha-2a increases 5-fluorouracil efficacy by elevating fluorouridine concentration in tumor tissue. , 1994, Anticancer research.

[4]  C. Allegra,et al.  Preclinical and clinical aspects of biomodulation of 5-fluorouracil. , 1994, Cancer treatment reviews.

[5]  S. Wadler.  Antineoplastic activity of the combination of 5-fluorouracil and interferon: preclinical and clinical results. , 1992, Seminars in oncology.

[6]  S. Wadler,et al.  Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells. , 1992, Biochemical and biophysical research communications.

[7]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Steinberg,et al.  A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Nordlinger,et al.  High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Wadler,et al.  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J G Fryer,et al.  A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. de Gramont,et al.  High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. , 1988, European journal of cancer & clinical oncology.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .